Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome
https://www.facingourrisk.org/research-clinical-trials/study/278/cancer-prevention-vaccine-nous-209-for-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05078866 (https://clinicaltrials.gov/show/NCT05078866)
Prevention study for people with Lynch syndrome
About the Study
This study is no longer enrolling people.
This study is testing a vaccine, known as the Nous-209 vaccine, which is intended to decrease the chances that people with Lynch syndrome will develop polyps that can turn into cancer.
People with Lynch syndrome who enroll in the study will participate for one year. It evaluates the safety and effectiveness of the Nous-209 vaccine in people affected with Lynch syndrome.
This Study is Open To:
This study is no longer enrolling people.
This Study is Not Open To:
This study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.